BCAX earnings analysis
What we found in BCAX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bicara remains a clinical-stage, pre-revenue biotech with diluted EPS of $(0.82) and a sharply higher net loss of $55.4 million in the second quarter. The $497.3 million cash, cash equivalents and marketable securities balance supports operations into the first half of 2029, and the company continues advancing ficerafusp alfa and FORTIFI-HN01. However, widening losses, patent litigation, China-linked manufacturing exposure and significant executive transitions temper the otherwise supportive cash-runway and clinical-execution outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash runway extends into 1H 2029
- Cash, cash equivalents and marketable securities totaled $497.3 million as of June 30, 2026. Management believes this is sufficient to fund operating expenses and capital expenditure requirements into the first half of 2029.
- Strong access to equity capital
- The company raised approximately $161.8 million of net proceeds in the February 2026 Offering and an additional $29.5 million of aggregate net proceeds through its ATM Program as of June 30, 2026.
- Clinical program remains active
- Bicara reported diluted EPS of $(0.82), compared with the $(0.81) consensus estimate. The company continues to advance ficerafusp alfa, including the Phase 2/3 FORTIFI-HN01 pivotal trial.
- No reported control deficiencies
- The company’s disclosure controls and procedures were assessed as effective at the reasonable assurance level as of June 30, 2026, and there were no material changes in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses are widening materially
- Net loss increased to $55.4 million for the three months ended June 30, 2026, from $27.4 million in the prior-year period; six-month net loss was $111.6 million versus $64.2 million. Management expects significant losses to continue and increase as development advances.
- CFO transition adds execution risk
- The CFO transition is effective August 12, 2026: Ivan Hyep will receive 12 months of salary continuation at a final base pay rate of $500,000, while Jennifer Larson becomes CFO with a $520,000 base salary and a 285,000-share stock option award.
- CEO succession creates uncertainty
- The CEO transition introduces multiple leadership changes: Claire Mazumdar will begin parental leave on September 1, 2026, Ryan Cohlhepp becomes Interim CEO on that date and CEO on January 1, 2027, and Tanya Green is scheduled to become COO on January 1, 2027.
- Patent litigation remains material
- The company is defending Y-Trap litigation involving inventorship and other claims related to patents licensed to Bicara; the court denied the motion to dismiss on September 30, 2025 and discovery remains ongoing. Separately, the PTAB instituted a post-grant review on July 15, 2026, with a final written decision anticipated by July 14, 2027.
- China-linked manufacturing exposure
- The company relies primarily on WuXi Biologics (Hong Kong) Limited for production needed to complete ongoing clinical trials and has no long-term supply agreements in place. The filing also identifies BIOSECURE Act implementation, with substantive prohibitions not expected before 2027, as a potential threat to Chinese biotech relationships and supply continuity.
- Additional financing may dilute holders
- Potential dilution remains significant: the company had 2,200,000 pre-funded warrants outstanding as of the filing date, and the ATM Program permits sales of up to $150.0 million of common stock. The company also has a $400.0 million shelf registration covering common stock, preferred stock, debt securities, warrants and units.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.82
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management states that $497.3 million of cash, cash equivalents and marketable securities is expected to fund operating expenses and capital expenditures into the first half of 2029.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Bicara Therapeutics (BCAX) reported its Q1 2026 financial results, showing continued challenges with net losses increasing to $56.2 million compared to $36.8 million in Q1 2025. Operating expenses surged, primarily…
- 10-K · March 30, 2026
- Bicara (BCAX) remains a clinical-stage biotech focused on ficerafusp alfa, a bifunctional EGFR-directed antibody with a TGF-β ligand trap. The company has advanced to a global Phase 2/3 FORTIFI-HN01 trial (1500 mg QW…
- 10-Q · November 10, 2025
- Bicara reported a Q3 net loss of $(36,330) thousand (EPS $(0.67)), driven by a sustained R&D ramp and higher operating expenses. Cash and investments remain sizable at approximately $407.6 million ($171,673 cash +…
- 10-Q · August 12, 2025
- Bicara reported no revenue and a wider Q2 net loss of $(27,388) (EPS $(0.50)) versus $(17,049) in Q2 2024; six‑month net loss was $(64,234) (EPS $(1.18)) compared with $(29,557) a year ago. Operating expenses increased…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCAX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever